Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | RXRB | P28702 | 3/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179243 | 0.92 | FOLH1 (0.42) | FOLH1LTA4HNPC1RAB9APOLB | |
| SCHEMBL20168691 | 0.90 | FOLH1 (0.47) | FOLH1LTA4HNR4A2RAB9ASMN1; SMN2 | |
| SCHEMBL20168306 | 0.90 | FOLH1 (0.42) | FOLH1LTA4HNPC1POLBSMN1; SMN2 | |
| SCHEMBL20168729 | 0.89 | FOLH1 (0.62) | FOLH1HSD17B10RXRARXRBNPC1 | |
| SCHEMBL21570571 | 0.87 | LMNA (0.46) | FOLH1LTA4HRXRANR4A2LMNA | |
| SCHEMBL20168587 | 0.85 | FOLH1 (0.50) | FOLH1LTA4H | |
| SCHEMBL20179186 | 0.84 | SLC7A5 (0.49) | FOLH1LTA4HRAB9ACACNA1BLMNA | |
| SCHEMBL21577913 | 0.84 | FOLH1 (0.48) | FOLH1HSD17B10RXRARXRBNPC1 | |
| SCHEMBL20179173 | 0.82 | SLC7A5 (0.44) | FOLH1LTA4HRXRACACNA1BLMNA | |
| SCHEMBL21577924 | 0.82 | PRSS1 (0.38) | FOLH1LTA4HNPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
| WO-2018094334-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | FOLH1 10/4885LTA4H 1303/4885HSD17B10 344/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | FOLH1 39/4885LTA4H 1571/4885HSD17B10 361/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | FOLH1 15/4885LTA4H 1594/4885HSD17B10 403/4885 |
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | TPI1, HPGDS, GPI | FOLH1 39/4885LTA4H 1571/4885HSD17B10 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.